Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:2994
Name germ cell cancer
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from germ cells.
Source DiseaseOntology.org
Alt Ids DOID:2157
Path disease disease of cellular proliferation cancer cell type cancer germ cell cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT positive Imatinib germ cell cancer no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00936936 Phase II Gemcitabine Ifosfamide Etoposide Melphalan Etoposide + Ifosfamide Docetaxel + Gemcitabine + Melphalan Bevacizumab + Carboplatin High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors Completed USA 0
NCT00983398 Phase Ib/II Pegfilgrastim Filgrastim Carboplatin + Melphalan Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Unknown status USA 0
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA 0
NCT01962896 Phase II Erlotinib + Sirolimus A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Terminated USA 0
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Completed USA | SWE | NOR | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BEL | AUT 2
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02300987 Phase II Ribociclib A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression Completed USA | NLD | FRA | ESP 0
NCT02429466 Phase I Cisplatin Guadecitabine Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Completed USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL 0
NCT02499952 Phase II Pembrolizumab Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Terminated USA 0
NCT02839694 Phase I Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn 0
NCT02988843 Phase II Bevacizumab + Brentuximab vedotin Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Terminated USA 0
NCT03158064 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Active, not recruiting USA 0
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03760081 Phase II ASP1650 A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors Completed USA 0
NCT04648826 Phase Ib/II Azacitidine + Bintrafusp alfa Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies Withdrawn USA 0
NCT04876456 Phase II Cabozantinib A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs Recruiting USA 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT06276491 Phase I XmAb541 Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors Recruiting USA 0
NCT06427941 Phase I BGB-B2033 BGB-B2033 + Tislelizumab A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | NZL 1